Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review.
Vicky ChenMorgan JonesLauren CohenWilson YangJasman BediHelen M MohanSameer S ApteJosé Tomas LarachMichael FloodAlexander HeriotJoseph KongSatish WarrierPublished in: Pleura and peritoneum (2022)
CRS-HIPEC has the potential to improve the overall survival in a highly selected group of SBA-PM patients, with 5-year survival rates comparable to those reported in colorectal peritoneal metastases. However, the expected survival benefits need to be balanced against the intrinsic risk of morbidity and mortality associated with the procedure. Further multicentre studies are required to assess the safety and feasibility of CRS-HIPEC in SBA-PM to guide best practice management for this rare disease.
Keyphrases
- small bowel
- minimally invasive
- particulate matter
- air pollution
- free survival
- squamous cell carcinoma
- primary care
- healthcare
- clinical trial
- heavy metals
- polycyclic aromatic hydrocarbons
- coronary artery bypass
- randomized controlled trial
- climate change
- risk assessment
- acute coronary syndrome
- percutaneous coronary intervention